Drug Profile
Cetuximab biobetter - Sinomab/Sorrento
Alternative Names: Cetuximab biosimilar/biobetter - Sinomab/Sorrento; CMAB 009; STI-001Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Mabtech
- Developer Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology; Sinomab
- Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Colorectal cancer
Most Recent Events
- 23 Aug 2023 National Medical Products Administration approves IND application for Cetuximab in colorectal cancer
- 20 Aug 2023 Cetiximab licensed to Simcere Zaiming in China for commercialization
- 20 Aug 2023 Preregistration for Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in China (IV)